Thursday, June 25, 2026
11 am EDT
View the recording
Many high value therapeutic targets, particularly multipass membrane proteins, remain untapped due to technical constraints such as sequence conservation and structural complexity. In this webinar, we will describe an accelerated pathway from discovery to preclinical candidate selection for these challenging targets. We will share key lessons learned from campaigns targeting more than 100 highly validated membrane protein targets that previously lacked antibodies, with insights for enabling target validation and preclinical candidate selection.
What You Will Learn:
- How advanced discovery strategies have unlocked 100+ ‘undruggable’ targets.
mRNA immunization, virus-like particles (VLPs), divergent avian host species, and other strategies have lowered the barriers to successful antibody generation against GPCRs, ion channels, and transporters involved in oncology, immune disorders, and metabolic disorders.
- Parallel engineering combined with AI/ML provides a faster pathway to a preclinical candidate. Comprehensive experimental data from CDR-Scanning (Paratope-PLUS®) enables AI/ML to simultaneously optimize therapeutic candidates for affinity, specificity, NHP cross-reactivity, and developability. Comprehensive datasets also provide the basis for stronger antibody IP by providing enablement and written description for antibody genus claims.
